Разработка научных основ создания технологии выделения и очистки генно-инженерных белков (1090305), страница 45
Текст из файла (страница 45)
Chromatogr. A. 1996. V.721. P.89-96.F292Sergeev N.V., Gloukhova N.S., Nazimov I.V., Miroshnikov A.I. / Monitoring ofRecombinant Human Insulin Production by Narrow-Bore Reversed-Phase High-PerformanceLiquid Chromatography, High-Performance Capillary Electrophoresis and Matrix-AssistedLASER Desorption Ionization Time-of-Flight Mass Spectrometry // J.
Chromatogr. A. 2001.V.907. P.131-144.F293Lough W.J., Wainer I.W. / High Performance Liquid Chromatography. FundamentalPrinciples and Practice // Blackie Academic & Professional, London, Glasgow, Weinheim,New York, Tokyo, Melbourne, Madras, 2000. P.1-282.F294Degerman M., Jakobsson N., Nilsson B. / Modeling and Optimization of PreparativeReversed-Phase Liquid Chromatography for Insulin Purification // J. Chromatogr. A. 2007.
V.1162 (1). P.41-49.F295Guiochon G., Felinger A., Shirazi D.G., Katti A.M. / Fundamentals of Preparative 12 andNonlinear Chromatography // Elsevier, San Diego, CA, 2006. P.1-262.F296The MathWorks Inc., Optimization Toolbox - For Use with MATLAB // MathWorks, 26Natick, MA, 2005.F297Poncin A. / Eurogentec Biologics Experience In the Field of Validation of theBiopharmaceutical Processes //Advancements, Applications and Theory in DownstreamProcessing, 5th HIC/RPC Bioseparation Conference, abstracts, Switzerland, Interlaken, 2007.F298Rodrigues R.C.R., Araujo J.M.M., Mota J.P.B.
/ Optimal Design and ExperimentalValidation of Synchronous, Asynchronous and Flow-Modulated, Simulated Moving-BedProcesses Using a Single-Column Setup // J. Chromatogr. A. 2007. 1162. P.14-23.F299A WHO Guide To Good Manufacturing Practice (GMP) Requirements, Part 2: Validation// Geneva: World Health Organization, 1997. P.1-100.F300Баирамашвили Д.И. / Рос. хим.
ж. 2005. Т. 49. № 1. С. 34-45.F301http://www.who.int/mediacentre/factsheets/fs312/ru/index.htmlF300F302Alastair J.J., Wood M.D. / N. Engl. Med. 1997. V. 337. P. 176-183.F303Setter S.M., Corbett C.F., Campbell P.K., White J.R. / Ann. Pharmacother. 2000. V. 34. P.1423-1431.F304Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrøm J, Hasselager E, LarsenUD, Ribel U, Schäffer L, Vad K, Jonassen I.
/ Soluble, fatty acid acylated insulins bind toalbumin and show protracted action in pigs // Diabetologia. 1996. V. 39. P. 281-288.F305Chance R. E., DiMarchi R. D., Frank B. H., Shields J. E. Insulin Analogs Modified atPosition 29 of the B Chain, United States Patent #5514646, 1996.F306Graumann K., Premstaller A.
/ J. Biotechnol. 2006. V. 1(2). P. 164 – 186.F307Winter J., Neubauer P., Glockshuber R., Rudolph R. / J. Boitechnol. 2000. V. 84. P.175-185.F308Гильчук П.В. / Биополимеры и клетки. 2004. Т. 20. С. 182-192.F309Hazra Partha / A process for preparation of insulin compounds, World IntellectualProperty Organization Patent Apllication, WO 2009/ 104199 A1, 2009.F310Lin L. / Dev. Biol.
Stand. 1998. V. 96, P. 97-104.F311Шмелев В.А., Чумбуридзе Г.Г. / Патент РФ № 2214832, 2012.F312Черепанов П.А., Павлов В.М., Федюкин В.С., Шматченко Н.А., Асташкина Г.Ф., Воротникова И.И., Гавриков В.Г., Байдусь А.Н., Михайлова Т.Г., Денисов Л.А., Ураков Н.Н., Степанов А.В. / Патент РФ № 2097428, 2009.F313Масычева В.И., Мирошников П.Н., Лебедев Л.Р.
/ Патент РФ № 2326944, 2014.F314Hoffman J.A., Lu J. FSH and FSH variant formulations, products and methods, UnitedStates Patent #7563763, 2009.F315Muda M., Jiang X., McKenna S.D. FSH mutants, United States Patent #7740862, 2010.F316Lustbader J. Long-acting follicle stimulating hormone analogues and uses thereof,United States Patent #7807620, 2010.F317Samaritani F., Donati P. Liquid pharmaceutical formulations of FSH and LH togetherwith a non-ionic, United States Patent #7741268, 2010.F318Rossi M. Method of purifying FSH, United States Patent #7754860, 2010.F319Samaritani F., Donati P.
Freeze-dried FSH/ LH formulations, United States Patent#7740884, 2010.F301F320http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR__Scientific_Discussion/human/000558/WC500029113.pdfF321Oliva A., Farina J., Llabres N. J. / Development of two high-performance liquidchromatographic methods for the analysis and characterization of insulin and its degradationproducts in pharmaceutical preparations.
// Chromatogr. B 2000. V.749. P.25-28.F322Brange J., Havelund S., Hougaard P. / Chemical stability of insulin. 2. Formation ofhigher molecular weight transformation products during storage of pharmaceuticalpreparations. // Pharm Res. 1992. V.6. P.727-734.F323Клюшниченко B. Е., Вульфсон А. Н. / Генно-инженерный инсулин человека. II. Эксклюзионная ВЭЖХ биотехнологических предшественников. Факторы, влияющие наразрешение и селективность // Биоорг. химия 1993. т.19.
№2. с.174-181.F324Tantipolphan R., Romeijn S., Engelsman J., Torosantucci R., Rasmussen T., Jiskoot W. /Elution behavior of insulin on high-performance size exclusion chromatography at neutralpH // Journal of Pharmaceutical and Biomedical Analysis 2010. V.52, №2. P.195-202.F325International Conference on Harmonisation of Technical Requirements for Registrationof Pharmaceuticals for Human Use, Validation of Analytical Procedures: Text andMethodology (Q2(R1)), Geneva2005.F326Guidance for industry: Bioanalytical method validation / US Department of Health andHuman Services, Food and Drug Administration, Rockville MD May 2001.F327The United States Pharmacopeia, Philadelphia PA USA 2000 (USP24) Suppl.
3.F328Dixon H.B., Perham R.N. / Reversible Blocking of Amino Groups withCitraconic Anhydride / Biochem. J. 1968. V.109. P.312-314.F329Shetty J.K., Kinsella J.E. / Ready Separation of Proteins from NucleoproteinComplexes by Reversible Modification of Lysine Residues // Biochem. J. 1980.V.191. P.269-272.F330Mossavarali S., Hosseinkhani S., Ranjbar B., Miroliaei M. / StepwiseModofocation of Lysine Residues of Glucose Oxidase with citraconic anhydride// International Journal of Biological Macromolecules.
2006. V.39. P.192-196.F331Sangeetha K., Abraham T.E. / Chemical Modification of Papain for Use inAlkaline Medium // Journal of Molecular Catalysis B: Enzymatic. 2006. V.38.P.171-177.F302F332http://www.sielc.com/pdf/Alternative%20Approach%20Protein%20Separation_Pittcon%202007.pdfF333Product monograph Lantus/sanofi-aventis Canada Inc. 52 p.F334Hiddemann W, Hoster E, Buske C et al. Rituximab is the essential treatment modalitythat underlies the significant improvement in short and long term outcome of patients withadvanced stage follicular lymphoma – a 10 year analysis of GLSG trials. Blood; ASH AnnualMeeting Abstracts, 2006: 108: Abstract 483.F335Forstpointner R., Unterhalt M. Dreyling M.Maintenance therapy with rituximab leads toa significant prolongation of response duration after salvage therapy with a combination ofrituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients withrecurring and refractory follicular and mantle cell lymphomas: results of a prospectiverandomized study of the German Low Grade Lymphoma Study Group (GLSG).
Blood 2006;108: 4003.F336Chaperot L., Jacob M.C., Levacon F. et al. // Leuk. Lymphoma.— 1997.— V. 28, N 1—2.— P. 133—143.F337Schulz H, Bohlius J, Skoetz N et al. Combined immunochemotherapy with rituximabimproves overall survival in patients with follicular and mantle cell lymphoma: updated metaanalysis results. Blood; ASH Annual Meeting Abstracts, 2006: 108: Abstract 2760.F338http://www.symbiotec.biz/en/company.htmlF339Gross, P., Jornvall, H., Thiry, M., Formicka-Zeppezauer, G., Zeppezauer, M. / Bis-MetHistones // World Intellectual Property Organization Patent Application, WO 2008/122434A1, 2008.F340http://www.ncbi/nlm/nih.gov/protein/4885377?report=genpeptF341Kratzmeier M., Albig W., Meergans T., and Doenecke D.
// Biochem. J. 1999. V.337. P.319-327.F342Волков Г.Л., Гаврилюк С.П., Скалка В.В., Краснобрижая Е.Н., Гаврилюк Е.С., Жукова А.И., Пурев Цэрэн Буха / Сравнительный анализ ионообменной мембранной хроматографии и хроматографии в упакованном слое при разделении можельной смесибелков из сыворотки молока // Биофарм.Ж. 2010. Т.2. №2. С.24-31.F343Tosoh Bioscience Chromatographic Process Media Catalogue, 2003.F344Dauwe Ch., White C.A.
/ Биофармацевтический журнал. Т.1. №1. С.17-22.F303F345Bloedorn B., Kuriyama N., White C.A. / Биофармацевтический журнал. Т.1. №2. С.2024.F346Majors R.E. / LC-GC N.Am. 2004. V.22 (5). P.416-428.F347http://www.uniprot.org/uniprot/P01579F348http://demoscope.ru/weekly/2010/0409/tema05.php#_FNR_17.F349http://www.uniprot.org/uniprot/C0KRQ8F350http://www.uniprot.org/uniprot/P01225F351Ulloa-Aguirre A, Damián-Matsumura P, Jiménez M, Zambrano E, Díaz-Sánchez V. /Biological characterization of the isoforms of urinary human follicle-stimulating hormonecontained in a purified commercial preparation // Hum Reprod.
1992. V.7(10). P.1371-1378.F352Fox K. M., Dias J. A., Van Roey P. / Three-Dimensional Structure of Human FollicleStimulating Hormone // Molecular Endocrinology, 2001, V.15 (3).P. 378–389.F353http://www.rcsb.org/pdb/explore/explore.do?structureId=1FL7F354http://www.sartorius.com/fileadmin/DID/pdf/DID_Lit_Collection/Data_Hydrocyclone_SBL2001-e.pdfF355http://www.who.int/bloodproducts/publications/WHO_TRS_924_A4.pdfF356http://www.rndsystems.com/pdf/5925-FS.pdfF357King J., Laemmli U.K. / Bacteriophage T4 tail assembly: structural proteins and theirgenetic identification. // J.Mol.Biol. 1973.
V75 (2), p. 315 – 324..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
